Profusa entered into Amendment No. 4 to its Note Modification and Conversion Agreement with NorthView Sponsor I LLC on November 5, 2026. The amendment changes the conversion price of the promissory note to the greater of a $0.20 floor price or the closing stock price on the day preceding the conversion notice. This adjustment applies to conversions initiated on or after the effective date. Profusa operates in the biotechnology sector, developing photodynamic therapies for cancer treatment.
